Nature of Business (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Nature of Business (Textual)
Cash and cash equivalents	$ 7,203,376	$ 7,200,271	$ 5,420,708	$ 8,983,717
Net change in cash and cash equivalent	$ 1,782,668	(1,783,446)
Percentage change in cash and cash equivalent	33.00%
Cash in operations	$ (2,695,073)	(2,293,303)
Working capital	1,181,249		1,181,249
Accumulated deficit	(183,106,946)		$ (175,525,612)
Increase in cash and cash equivalents	$ 2,041,871
Increase in working capital, percentage	173.00%
Net loss	$ (7,581,334)	$ (1,639,627)
Remaining from FBR sales agreement, description	The Company has up to $8.9 million remaining from the FBR Sales Agreement as of May 8, 2020 under the prospectus supplement filed April 10, 2020.
Contracts from NIH and NIAID, description	The Company is currently developing RiVax® under a NIAID contract of up to $21.2 million over six years, and a one-year NIH grant of $150,000 in support of its SGX942 pediatric program. In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilization technology, and a Defense Threat Reduction Agency subcontract of approximately $600,000 over three years for SGX943.
Government contract and grant funding available	$ 1,960,000